646 jili jackpot slot

WEST PALM BEACH, Fla. (AP) — If last month’s election wasn’t painful enough for Florida Democrats, they’re losing another state House seat after one of their members announced Monday that she’s switching parties. State Rep. Susan Valdés, a former school board member who was reelected as a Democrat last month, said on X that she is “tired of being the party of protesting.” Valdés ran to be chairperson for her local county’s Democratic executive committee earlier this month. She won her current term by nearly 5 percentage points but can’t run for reelection again because of term limits. Republicans have controlled the governor’s office and both branches of the Legislature since 1999. Valdés is serving her final two years before leaving office due to term limits. Republicans now have an 86-34 majority in the House. “I got into politics to be part of the party of progress,” Valdés wrote. “I know that I won’t agree with my fellow Republican House members on every issue, but I know that in their caucus, I will be welcomed and treated with respect.” House Speaker Daniel Perez reposted Valdés’ statement and welcomed her into the House, where Republicans have a supermajority of 86-34. House Democratic Leader Fentrice Driskell said she was surprised and disappointed by Valdés’ announcement. “It is sad that she has elevated her own aspirations above the needs of her district,” Driskell wrote in a statement on X.

METAIRIE, La. (AP) — If Saints interim coach Darren Rizzi has any definite ideas about who'll play quarterback for New Orleans against Washington on Sunday, he's not ready to share that information. Rizzi maintained on Wednesday that there's still a chance that Derek Carr could clear the concussion protocol and function well enough with his injured, non-throwing left hand to return against the Commanders. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week'We need new leadership': Atlantic Liberal caucus calls for Trudeau's resignation

Kings vs. Pelicans Injury Report Today – December 12NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global heparin market size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.22% during the forecast period. Increasing prevalence of coagulation disorders is driving market growth, with a trend towards increasing R and D activities and new therapeutic applications of heparin. However, side effects of heparin poses a challenge. Key market players include Aspen Pharmacare Holdings Ltd, B.Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., Viatris Inc., Opocrin SpA, Pfizer Inc.; GlaxoSmithKline plc; Sandoz (Novartis AG) Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Heparin Market Scope Report Coverage Details Base year 2023 Historic period 2018 - 2022 Forecast period 2024-2028 Growth momentum & CAGR Accelerate at a CAGR of 7.22% Market growth 2024-2028 USD 3.34 billion Market structure Fragmented YoY growth 2022-2023 (%) 6.75 Regional analysis Europe, North America, Asia, and Rest of World (ROW) Performing market contribution Europe at 34% Key countries US, UK, Germany, France, China, Canada; Italy; Spain; Denmark; Sweden; Norway; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait Key companies profiled Aspen Pharmacare Holdings Ltd, B.Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., Viatris Inc., Opocrin SpA, Pfizer Inc.; GlaxoSmithKline plc; Sandoz (Novartis AG) Market Driver The Heparin market is experiencing significant growth due to the rising prevalence of venous thromboembolism (VTE) and blood clotting disorders. VTE includes deep vein thrombosis and pulmonary embolism, which can lead to serious complications like heart attacks and strokes. Heparin, an injectable anticoagulant, is widely used to prevent blood clotting in veins and arteries. Both unfractionated heparin, derived from animal sources like bovine and porcine, and plasma-derived therapies (PDTs) are popular. However, challenges like fungal infections, counterfeit drugs, and chronic diseases such as diabetes, cancer, and cardiovascular diseases (CVD) increase the market demand. The geriatric population, accident victims, and those with orthopedic disorders are significant patient groups. Heparin is administered via subcutaneous injection or intravenous infusion, depending on the condition. Major players include Baxter International's Optimvia, which offers both bovine and porcine heparin. Other applications include atrial fibrillation and thromboprophylaxis. Heparin, discovered in 1961, is a universal anticoagulant used to treat hemostasis and thrombosis. Its applications in surgery, interventions, and medicine have significantly impacted healthcare. Major advancements include fractionated heparin and low-molecular-weight heparin, expanding thrombosis management options. These developments have revolutionized scientific approaches to heparin use. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This heparin market report extensively covers market segmentation by 1.1 Low-molecular-weight heparin- Low-molecular-weight heparin (LMWH) is a type of heparin derived from unfractionated heparin through chemical or enzymatic methods. It inhibits coagulation by activating antithrombin III, preventing the activation of factor Xa and subsequent conversion of prothrombin to thrombin, and the formation of fibrin from fibrinogen. LMWH has several advantages over unfractionated heparin, including improved bioavailability, prolonged antithrombotic activity, and reduced need for regular blood monitoring. The British National Formulary and the National Institute for Health and Care Excellence have approved LMWH for various clinical indications, including deep vein thrombosis prophylaxis in medium- and high-risk groups, treatment of deep vein thrombosis and pulmonary embolism in nonpregnant women, treatment of venous thromboembolism in pregnancy, treatment of ST-elevation myocardial infarction in patients undergoing percutaneous coronary intervention, and prevention of clotting in extracorporeal circuits. Unfractionated heparin and LMWH are self-administered subcutaneously. Several LMWH options are available in the market, including Fragmin (dalteparin), Lovenox (enoxaparin), parnaparin, certoparin, nadroparin, reviparin, and bemiparin. Each product has unique advantages, such as improved bioavailability, longer half-life, and lower incidence of adverse effects. For instance, dalteparin has a mean molecular weight of approximately 5,000 Da, improved bioavailability, and a lower incidence of heparin-induced thrombocytopenia and thrombosis. Lovenox (enoxaparin) is associated with a low incidence of adverse effects and a reduced need for laboratory monitoring. Parnaparin has greater efficacy, greater bioavailability, and a longer half-life, permitting once-daily administration. Certoparin has been proven effective and safe in preventing venous thromboembolism in different medical and surgical settings. Nadroparin has a greater ratio of anti-factor Xa to anti-factor Ha activity, greater bioavailability, and a longer duration of action. Reviparin has a narrow molecular weight distribution profile and is effective in preventing deep vein thrombosis at different daily doses. Bemiparin has the lowest mean molecular weight, the longest half-life, and the largest anti-factor Xa activity, making it effective in preventing venous thromboembolism in moderate- and high-risk surgical patients and during hemodialysis. The wide availability of LMWH products and their advantages and efficacy increase the adoption of LMWH, contributing to the growth of the LMWH segment in the global heparin market during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Heparin market refers to the global trade of Heparin, an essential injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is primarily used to manage Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins, which can lead to serious complications like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Accidents, chronic blood diseases such as diabetes, and the elderly demographic are significant risk factors for VTE. Heparin is also used to prevent arterial thromboembolism and is crucial in the blood donation system to prevent clotting. Unfractionated heparin, an animal-derived product, is the most commonly used form of heparin. Plasma-derived therapies (PDTs) are alternative options. Heparin is administered through subcutaneous or intravenous (IV) methods and is used to manage conditions like Atrial Fibrillation and blood clotting disorders. Market Research Overview The Heparin market refers to the global trade of heparin, an injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is primarily used to manage Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins, which can lead to complications such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Heparin is also used to prevent clots in arteries, particularly in patients with conditions like atrial fibrillation, heart attacks, and strokes. This drug is derived from animal sources, including porcine and bovine, and is administered either subcutaneously or intravenously. Heparin is essential in managing chronic diseases like diabetes, cancer, and chronic respiratory diseases, as well as noncommunicable diseases (NCDs) and cardiovascular diseases (CVD). However, the market faces challenges such as counterfeit drugs, fungal infections, and the risk of bleeding. The geriatric population and patients with orthopedic disorders are significant consumer groups. Heparin comes in different forms, including Unfractionated Heparin and Plasma-derived therapies (PDTs). It is used in clinics for various indications, including subcutaneous administration for DVT prevention and intravenous infusion for acute PE treatment. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.com Website: www.technavio.com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/heparin-market-to-grow-by-usd-3-34-billion-2024-2028-driven-by-coagulation-disorder-prevalence-and-ai-impacting-market-trends---technavio-302328479.html SOURCE TechnavioEx-Celtic star John Hartson's punch up with Hollywood hard-man Vinnie Jones

A provincial mining industry leader says B.C. could end up profiting from trade tensions between China and the United States over critical minerals. Michael Goehring, president and chief executive officer of the Mining Association of British Columbia, said Wednesday, (Dec. 4), that China's decision to ban exports of certain critical minerals and rare earths to the United States demonstrates why it is "vital" for Canada and the U.S. to reduce their dependence on authoritarian regimes for critical mineral supplies and mineral processing. "British Columbians can play a key role in providing the critical minerals the U.S. and our other allies need in the years to come," Goehring said. "B.C. has, or produces, 16 of the 50 minerals the United States has identified as being critical to the nation’s economic and national security. In fact, seven per cent of B.C.’s exports to the US in 2022 were critical minerals and metals, including aluminum, germanium, gallium, indium, lead and zinc." China announced Tuesday, (Dec. 3), that it would immediately ban sales of gallium and germanium among other minerals to the United States following the U.S.'s decision to limit Chinese access to American-made digital technology. China is world's leading supplier of many minerals used in technologies deemed critical in fields like transportation, communication and alternative energy, all of which have a military and security dimension. Chinese efforts to use its dominance in these materials as leverage have not gone unnoticed, as several western jurisdictions have sought out alternative suppliers, including Canada. "In fact, Canada and the U.S. initiated the Joint Action Plan on Critical Minerals Collaboration in 2020 under President Trump to reduce our vulnerability," Goehring said." China’s export ban highlights the need to accelerate our efforts through the Joint Action Plan to grow a resilient North American critical mineral supply chain and advance our mutual economic, defense and security objectives." Whether Goehring's appeal will resonate among decision-makers on either side of the U.S-Canada border is a different question given the prospect of trade tensions with Trump returning to the White House next month. With 17 new critical mineral projects under development, Britisch Columbia can make what Goehring called "a meaningful contribution to North America’s future" while creating jobs for workers, stability for resource communities and shared prosperity throughout B.C. "But these benefits can only be realized if we modernize and expedite the mine permitting and approval process," he said. "(We) are in a race and we need to act quickly. Ongoing permitting delays and uncertainty needlessly drive away investment and lead to deferred or unrealized economic benefits. We need mine permitting to be a competitive advantage for our province."Mr Carter, a former peanut farmer, served one term in the White House between 1977 and 1981, taking over in the wake of the Watergate scandal and the end of the Vietnam War. After his defeat by Ronald Reagan, he spent his post-presidency years as a global humanitarian, winning the Nobel Peace Prize in 2002. His death on Sunday was announced by his family and came more than a year after he decided to enter hospice care. He was the longest-lived US president. His son, Chip Carter, said: “My father was a hero, not only to me but to everyone who believes in peace, human rights and unselfish love. “My brothers, sister and I shared him with the rest of the world through these common beliefs. “The world is our family because of the way he brought people together, and we thank you for honouring his memory by continuing to live these shared beliefs.” World leaders have paid tribute to Mr Carter, including US President Joe Biden, who was one of the first politicians to endorse Mr Carter for president in 1976 and said the world had “lost an extraordinary leader, statesman and humanitarian”. He said: “Over six decades, we had the honour of calling Jimmy Carter a dear friend. But, what’s extraordinary about Jimmy Carter, though, is that millions of people throughout America and the world who never met him thought of him as a dear friend as well. Our founder, former U.S. President Jimmy Carter, passed away this afternoon in Plains, Georgia. — The Carter Center (@CarterCenter) “With his compassion and moral clarity, he worked to eradicate disease, forge peace, advance civil rights and human rights, promote free and fair elections, house the homeless, and always advocate for the least among us. “He saved, lifted, and changed the lives of people all across the globe.” Irish President Michael D Higgins said Mr Carter was “a principled man who dedicated his life to seeking to advance the cause of peace across the world”. He added: “On behalf of the people of Ireland, may I express my sympathies to President Carter’s children and extended family, to President Joe Biden, to the people of the United States, and to his wide circle of colleagues and friends across the globe.” Mr Carter is expected to receive a state funeral featuring public observances in Atlanta and Washington DC before being buried in his home town of Plains, Georgia. A moderate democrat born in Plains in October 1924, Mr Carter’s political career took him from the Georgia state senate to the state governorship and finally, the White House, where he took office as the 39th president. His presidency saw economic disruption amid volatile oil prices, along with social tensions at home and challenges abroad including the Iranian revolution that sparked a 444-day hostage crisis at the US embassy in Tehran. But he also brokered the Camp David Accords between Egypt and Israel, which led to a peace treaty between the two countries in 1979. After his defeat in the 1980 presidential election, he worked for more than four decades leading the Carter Centre, which he and his late wife Rosalynn co-founded in 1982 to “wage peace, fight disease, and build hope”. Under his leadership, the Carter Center managed to virtually eliminate Guinea Worm disease, which has gone from affecting 3.5 million people in Africa and Asia in 1986 to just 14 in 2023. Mrs Carter, who died last year aged 96, had played a more active role in her husband’s presidency than previous first ladies, with Mr Carter saying she had been “my equal partner in everything I ever accomplished”. Earlier this year, on his 100th birthday, Mr Carter received a private congratulatory message from the King, expressing admiration for his life of public service.

Inflation, growth, and rupee stability will be focus areas for new RBI Governor: KV Kamath

Brock Bowers sets NFL rookie records as the Raiders roll to a 25-10 victory over the SaintsLIBERTY LAKE, Wash., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, marks a significant milestone with the 50th deployment of its Temetra ® solution in Australia, which is being deployed by Aqwest, the provider of drinking water to the City of Bunbury and its surrounding areas in Western Australia. With Itron’s cloud-based multi-vendor meter data collection and management solution, Aqwest will be able to manage its existing mechanical meters while enhancing and optimizing operations. Aqwest selected Temetra, Itron’s innovative cloud-based solution, to simplify meter data collection by utilizing a solution capable of incorporating multi-vendor meter reads. With the adoption of Temetra, Aqwest can now upgrade to digital meters at a pace best suited for its operations and seamlessly collect meter readings from existing mechanical meters and future smart meters through a single data collection and management platform. This multi-vendor capability allows Aqwest to gain comprehensive insights into consumption patterns through one unified platform. Utilizing Aqwest’s existing communication protocols and meter vendors, Temetra will collect, record and upload meter data using the handheld mobile Android devices currently in use by the utility. Temetra provides valuable insights by analyzing both current reads and historical data, enabling Aqwest to address customer billing questions and detect potential water leaks. This 50th customer milestone reinforces Itron’s commitment to addressing water scarcity in Australia and ensuring that communities are better equipped to manage water operations. The Temetra solution enables utilities to address critical water management tasks more efficiently. These capabilities are key to helping utilities anticipate and address potential water challenges before they turn into a crisis, such as losing water within the distribution system. “Aqwest is committed to providing sustainable, high-quality drinking water to the Bunbury Region. As the effects of climate change continue to impact on local water security, having an efficient water management system in place is crucial,” said Gary Hallsworth, chief executive officer at Aqwest. “We are delighted to be working with Itron to upgrade our water metering infrastructure to improve our customer consumption data and billing capabilities.” “Australia is no stranger to water shortages due to its dry climate, recurring droughts and the challenges caused by climate disruption, making water management a complex issue. On top of these challenges, population growth is increasing the demand on existing water infrastructure, much of which is aging and prone to inefficiencies,” said Don Reeves, senior vice president of Outcomes at Itron. “We are excited to celebrate this significant milestone. Working together with Australian utilities, we strive to deploy efficient solutions to address these challenges and to ensure that both remote and urban communities are equipped to tackle water management. With Temetra, utilities across the country are another step closer to water security.” Temetra is a globally adopted, cloud-based, multi-vendor, multi-commodity, meter data management solution. Temetra supports a variety of meter manufacturers and communications protocols enabling a smooth migration from automated meter reading to advanced meter reading. Temetra’s open ecosystem solution enables interoperability at all levels and supports multiple data collection technologies concurrently, providing utilities a smooth migration path from manual to smart metering. Storing meter read data from a variety of sources in one location, combined with other innovations like map-based routing, enhances operational efficiency. Temetra has demonstrated scalability, accommodating thousands of customers ranging in size from several hundred meters to several million. About Itron Itron is a proven global leader in energy, water, smart city, IIoT and intelligent infrastructure services. For utilities, cities and society, we build innovative systems, create new efficiencies, connect communities, encourage conservation and increase resourcefulness. By safeguarding our invaluable natural resources today and tomorrow, we improve the quality of life for people around the world. Join us: www.itron.com . Itron®, the Itron Logo and Temetra are registered trademarks of Itron, Inc in the United States and other countries and jurisdictions. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated. For additional information, contact: Itron, Inc. Sharon Chong Field Marketing Manager, Asia Pacific Office: +65 69837687 sharon.chong@itron.com Paul Vincent Vice President, Investor Relations 512-560-1172 Investors@itron.com Itron, Inc.

The Premier League table is starting to have a 1979 kind of feel to it — with Liverpool at the top of the standings and Nottingham Forest in second place as the closest challenger. Liverpool padded its lead with a 5-0 rout of West Ham on Sunday, while upstart Nottingham Forest climbed into second place by beating Everton 2-0 to continue its surprising push for a Champions League place. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen20 Best Gifts From Todd Snyder’s Luxury Holiday Guide That They Won’t Return